BiotechTube
Home/Bristol Myers Squibb/Christopher Boerner
CB

Christopher Boerner

Chief Executive Officer

Bristol Myers Squibb

Therapeutic Areas

OncologyHematologyCardiovascular DiseaseImmunologyNeuroscience

Bristol Myers Squibb Pipeline

DrugIndicationPhase
Cilta-cel (Carvykti)Multiple MyelomaPhase 3
Abecma (ide-cel)Multiple MyelomaPhase 3
Breyanzi (liso-cel)Follicular Lymphoma, CLL/SLLPhase 3
Orca-THematologic MalignanciesPhase 3
CC-92480 (Mezigdomide)Multiple MyelomaPhase 3
CC-99282 (BMS-986393)Multiple Myeloma, DLBCLPhase 1/2
BMS-986278Idiopathic Pulmonary Fibrosis (IPF)Phase 3
MilvexianStroke Prevention, ACSPhase 3

Leadership Team at Bristol Myers Squibb

DE
David Elkins
Chief Financial Officer
RP
Robert Plenge
Chief Research Officer
AL
Adam Lenkowsky
Chief Commercialization Officer
EM
Elizabeth Mily
EVP, Strategy & Business Development
KH
Karin Hehenberger
Chief Medical Officer
View full Bristol Myers Squibb profile